Nanologica has entered the insulin market in China with an order of approximately SEK 2m for the company's silica-based purification media NLAB Saga.
The customer is an insulin manufacturer and the order relates to the evaluation of NLAB Saga on a production scale.
This is Nanologica's first order regarding the evaluation of NLAB Saga for insulin manufacturing on the Chinese market.
Nanologica’s team has worked with this customer for a few years and the customer has now acknowledged Nanologica’s products and expertise and is now moving forward to evaluate NLAB Saga on a manufacturing scale with the purpose of including it in its manufacturing.
"After having received a number of orders regarding NLAB Saga for the production of GLP-1 analogues, it is now very gratifying to receive this order for insulin production," said Nanologica's CEO Andreas Bhagwani.
He continued: "Initially, we built our case and our production line to be able to supply silica to insulin manufacturers."
"This order is a big step in the right direction and indicates that we will be able to sell our various product types and not just the one generally used for the purification of GLP-1 analogues."
"Our team has done a tremendous job with this customer, who is now opening up to changing their process as they see we can help them lower their manufacturing costs."
"We have the now requested product type in stock and we will thus be able to deliver immediately against this order."
The order value is approximately SEK 2m at today's exchange rate and will be delivered immediately.